Trial Profile
Evaluation of Effectiveness and Safety of XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Sep 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms IRIS-XPEDITION
- 15 Dec 2020 Planned End Date changed from 1 May 2024 to 1 Jul 2024.
- 26 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 19 Dec 2018 Planned End Date changed from 1 Jun 2023 to 1 May 2024.